Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 463 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Impax intends to slash 110 jobs

Primarily affecting manufacturing operations, the company expects reduction in both personnel and other variable expenses, including the product discontinuances, to yield an annual cost savings of approximately $15.0m.